1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Ironwood’s Phase III Data Could Expand Linzess Market Share

 
• By Alaric DeArment

The company also hopes that positive safety data for pediatric patients could help with discussions with the FDA to make an OTC version of the drug.

Phase III pediatric data could expand market share for Ironwood's Linzess • Source: Shutterstock

Ironwood Pharmaceuticals, Inc. stands to potentially expand the market position of Linzess (linaclotide) in the treatment of bowel diseases with new topline data showing the drug is safe and effective in treating pediatric patients with functional constipation (FC). Moreover, it could also help the company’s efforts to create an over-the-counter version of the drug down the line.

Ironwood announced results from its Phase III trial of Linzess at 72mcg in patients aged 6-17 with FC, a condition that affects an estimated 4 million to 6 million children...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.